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Introduction
Acetylcholine is a neurotransmitter distributed extensively
throughout the central nervous system (CNS). It modulates
neuronal activity through agonist effects on muscarinic and
nicotinic receptors. Acetylcholinesterase inhibitors (ChEIs)
enhance neuronal transmission by preventing the hydroly-
sis of acetylcholine by the enzyme acetylcholinesterase,
thus increasing the availability of acetylcholine in muscar-
inic and nicotinic receptors.
Cholinergic neurons demonstrate extensive distribu-
tion throughout the CNS and the peripheral nervous
system. In the CNS they are believed to be associated with
cognitive functions. One of the hypotheses of the origin of
Alzheimer’s disease (AD) postulates loss of cholinergic
neurons as the primary cause. ChEIs have been used
successfully in the improvement of cognition and slowing
of cognitive deterioration in AD patients. It is believed that
increased cholinergic tone is responsible for the beneficial
effect of ChEIs on cognition.
In addition to effects on cognition, sporadic reports,
mainly in the latter half of the 20th century, have suggested
that cholinergic mechanisms may have a role in the
modulation of human mood and behavior. Anecdotal
reports date back to as early as 1889 when Willoughby [1]
reported the resolution of manic symptoms following
intravenous administration of pilocarpine. In the 1950s
use of cholinesterase inhibitors in the form of organo-
phosphate insecticides was found to be associated with an
unusual frequency of depressive and psychotic symptoms
[2,3,4]. In 1972 Janowsky et al. [5,6] published a report
describing the resolution of manic symptoms following
intravenous administration of the ChEI physostigmine and
postulated the cholinergic-adrenergic hypothesis of mania
and depression. According to the hypothesis, cholinergic
and adrenergic tone had reciprocating and balancing
effects on mood, adrenergic tone being manicogenic or
antidepressant, and cholinergic tone being depressogenic
or antimanic. In further support of the hypothesis were
observations that cholinergic antagonist such as scopola-
mine may induce euphoria, talkativeness, difficulties in
concentration, and flight of ideas [7], and that cholino-
mimetics may cause changes in sleep patterns (eg, decrease
REM latency) and hormone levels (eg, adrenocorticotropic
hormone [ACTH], cortisol) similar to those found in
patients with major depression [8,9].
Critics of the cholinergic-adrenergic hypothesis claimed
that the behavioral effects observed with ChEIs are
secondary and nonspecific reaction to the wide range of
unpleasant peripheral side effects they generate and the
stress and malaise that ensue [10,11]. The short half-life
(10–20 minutes) of physostigmine, the presence of central
as well as peripheral effects, and the obligatory intravenous
administration, were considered significant obstacles to the
testing of the effects of ChEIs on mood and behavior [12].
In the past decade, the advent of orally administered
ChEIs, with longer half-life and a more tolerable side-effect
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474 Mood Disordersprofile, developed mainly for the treatment of cognitive
deficits in AD, has led to an increasing number of reports
on the effects of ChEIs in mood and behavior. This review
focuses mainly on advancements made in the field over the
past 2 to 3 years.
Properties of Cholinesterase Inhibitors
As a class ChEIs share a propensity for certain side effects.
These include nausea, vomiting, anorexia, diarrhea,
insomnia, fatigue, muscle cramps, and headache. The
frequency and severity of these side effects vary substantially
from compound to compound and appear to be related to
the rate at which the dose of the compound is increased.
Donepezil
Donepezil hydrochloride is a reversible inhibitor of the
enzyme acetylcholinesterase. The elimination half-life of
donepezil is about 70 hours and pharmacokinetics are
linear. It is approximately 96% bound to plasma proteins,
although it was not found to have any significant effects on
the binding of other highly protein bound drugs, including
warfarin, digoxin, and furosemide. Nor do these drugs
significantly affect donepezil. Donepezil is both excreted
in the urine intact and extensively metabolized by CYP 450
isoenzymes 2D6 and 3A4 and by undergoing glucuronida-
tion. Donepezil has greater selectivity for acetylcholinest-
erase (AChE), the type of ChE prevalent in the CNS, than it
has for butylcholinesterase (BChE), the type of ChE which
is primarily active outside of the blood brain barrier. The
AChE:BChE ratio of donepezil (1200:1) is the highest
available in this class of agents. This leads to increased
central versus peripheral cholinergic specificity and is
believed to be responsible for the favorable side effect
profile of donepezil [13].
Tacrine
Tacrine hydrochloride is a reversible inhibitor of the
enzyme acetylcholinesterase. Tacrine inhibits both AChE
and BChE; but it is more selective for AChE than physo-
stigmine. Tacrine undergoes extensive hepatic metabolism
by the cytochrome P450 1A2 isoenzyme to at least three
metabolites. The major metabolite, 1-hydroxy-tacrine
(velnacrine), is active. Metabolites are excreted in the urine.
Elimination half-life is between 1.5 and 4 hours. Tacrine is
known to produce significant elevations in liver enzymes,
notably the transaminases. These elevations are generally
reversible and tend to be higher in women.
Rivastigmine
Rivastigmine is a carbamate–type pseudo–irreversible
ChEI. Rivastigmine is not metabolized by the hepatic
cytochrome P450 oxidative enzyme system and it exhibits
approximately 40% protein-binding. Thus, drug inter-
actions with rivastigmine are unlikely. Rivastigmine is
rapidly and extensively metabolized primarily at CNS
receptor sites via cholinesterase. The plasma half-lives of
rivastigmine and the major metabolite are roughly 1 hour
and 2 hours, respectively; however, the cholinesterase
inhibition in the CNS lasts much longer (average 10 hours)
than the short plasma half-life would predict. This is due to
the fact that when rivastigmine's phenolic ZNN-666
metabolite is formed, it leaves behind a carbamate moiety
that stays attached to the AChE receptor for up to 10 hours,
which prevents the hydrolysis of ACh. Renal excretion of
the metabolite is the major route of elimination.
Metrifonate
Metrifonate differs from other AChE inhibitors in that it is
a prodrug that is nonenzymatically converted in vivo to the
active moiety 2,2-dichlorovinyl dimethylphosphate
(DDVP). DDVP administered alone has a very short
plasma elimination half-life, but small amounts released
from metrifonate are sufficient to inhibit AChE activity in
vivo. DDVP is an irreversible inhibitor of AChE and activity
is maintained for several weeks. It also inhibits BChE.
Metrifonate has been withdrawn from marketing consider-
ation due to safety concerns.
Galantamine
Galantamine is a reversible, competitive cholinesterase
inhibitor. In addition, it allosterically modulates nicotinic
acetylcholine receptors. Galantamine is approximately 50
times more effective against human AChE than against
human BChE at therapeutic doses.
Controlled Release Physostigmine
A new extended-release formulation of physostigmine
salicylate that yields sustained blood levels, permitting
twice-daily dosing. It inhibits both AChE and BChE.
It is associated with high frequency of gastrointestinal
side effects.
Effect of Cholinesterase Inhibitors on Mood 
and Behavior in Alzheimer’s Disease
Most available cholinesterase inhibitors exhibit a similar
beneficial effect on cognition in AD patients. Patients with
AD, however, typically present with a variety of neuro-
psychiatric symptoms including depression, apathy,
agitation, hallucinations and psychosis. In addition,
patients’ ability to perform activities of daily living (ADL)
is a crucial factor in the assessment of their disability, the
burden on caregivers, and whether they require placement
in a nursing facility or not. As a consequence, studies of
ChEIs in AD started to include, in addition to measures of
cognitive function, also measures of mood and behavior,
such as the Neuropsychiatric Inventory (NPI) [14].
Donepezil
Donepezil was associated with the largest number of posi-
tive observations supporting a beneficial effect on mood
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donepezil administration was associated with prevention
of worsening depression and behavioral dysregulation over
a 12-month period in AD patients. [15] Cummings et al.
[16] reported that AD patients taking donepezil had lower
lever of behavioral disturbances, were less threatening, and
needed fewer sedatives than those not on donepezil as
reported by caregivers after a 6-month treatment period. In
an open-label study of 2092 patients with mild-moderate
AD donepezil improved ADL, mood, social behavior, and
disturbing behavior, as well as memory after 3 months
when compared with baseline. Improvements were
specifically reported in urinary incontinence, nighttime
restlessness, irritability, aggressive behavior, stubbornness,
wandering, and bowel control [17]. Hecker [18] reported
improvement with donepezil in depression, anxiety,
and apathy areas of the NPI when compared with placebo
over 4 and 24 weeks in 191 moderate-severe AD patients.
In a retrospective study in 86 AD patients Mega et al. [19]
observed significant improvement from baseline in
delusions, agitation, anxiety, disinhibition, and irritability
in responders to donepezil. The behavioral changes were
dose-dependent. They concluded that donepezil has
psychotropic properties, and pretreatment behaviors help
predict patients’ responses to treatment. The same group
also demonstrated that AD patients that responded to
donepezil with reduction of irritability, delusions,
hallucinations, agitation, euphoria, and aberrant motor
behavior, also demonstrated lower regional perfusion in
the dorsolateral parietal, orbital frontal, and anterior
cingulated bilaterally [20]. More recently they reported
that AD patients who responded to ChEI therapy had
significantly more pretreatment irritability, disinhibition,
and euphoria than nonresponders on the NPI, and
significantly lower lateral orbital frontal (P < 0.00001) and
dorsolateral frontal (P <0.0005) perfusion bilaterally as
evidenced by 99m labelled D, L-hexamethyly-propylene
amine oxime (99m Tem-HMPAO) single photon emission
computed tomography. They concluded that a pre-
t r ea tment  orb i to f ron ta l  syndro me may  pred i c t
behavioral response to ChEI therapy in AD [21•].
Metrifonate in Alzheimer’s disease
Several studies have demonstrated the efficacy of metri-
fonate in improving neuropsychiatric symptoms in AD
patients. Kaufer [22•] reported beneficial effects of metri-
fonate in AD patients on the NPI total score, aberrant
motor behavior, and in symptoms of depression, apathy
and hallucinations when compared with placebo in a 26-
week trial. In a study by Morris et al. [23] metrifonate was
associated with improvements in behavioral and global
functioning as well as cognitive functioning in mild-
moderate AD patients over a 36-week period when
compared with placebo. Cummings et al. [24] and
Raskind et al. [25] reported similar results in mild-moder-
ate AD patients over a 6-month period as measured by the
NPI. In a negative study, Becker et al. [26] reported that
although metrifonate was associated with slowing the
severity of cognitive symptoms in AD patients over a 6-
month period, it did not affect noncognitive behaviors
measured by the AD Assessment Scale noncognitive
subscale (ADAS-N), Global Improvement Scale, or the
ADL Checklist.
Other acetylcholinesterase inhibitors 
in Alzheimer’s disease
Tacrine was associated with a higher percentage of patients
exhibiting improvement on the Alzheimer's Disease
Assessment Scale (ADAS) noncognitive items: cooperation,
delusions, and pacing, as well as improvement in cogni-
tion when compared with placebo in a 30-week trial [27].
Rivastigmine was associated with significant improve-
ment in activities of daily living, and global evaluation
ratings in addition to cognitive functioning when compared
with placebo in mild-moderate AD patients over a 6-month
period. Twenty three percent of patients taking rivastigmine
discontinued due to adverse events compared with 7% in
the placebo group [28].
In a 5-month placebo-controlled study in mild to mod-
erate AD patients, galantamine was associated with
improvement in behavior and functioning as measured by
the Clinician’s Interview-Based Impression of Change,
Caregiver Input, and AD Cooperative Study ADL Inventory,
as well as improvement in cognition as measured by the
AD Assessment Scale cognitive subscale [29]. In another
study in mild-moderate AD patients, improvements in
functioning and cognition were observed at 6 months on
galantamine versus placebo [30].
In two studies involving extended release physostigmine
there was a significant improvement in global functioning as
well as cognitive functioning when compared with placebo
in mild-moderate AD patients, but the treatment was
also associated with a high incidence of adverse events
(in one study 78.6% of patients experienced nausea, 61.5%
vomiting; in the other study 37.6% of patients discontinued
the study due to adverse events) [31, 32].
In view of the beneficial effect of ChEIs on cognition,
and considering the relationship between cognition,
mood, and behavior, on biologic, psychologic, and social
levels, the primary effect of ChEIs on mood and behavior
needs to be established especially in patients with pre-
existing cognitive deficits. For example, improved
cognition may in itself be responsible for improvement in
mood and behavior: patients with impaired skills that are
necessary for ADL and social integration may be observed
to demonstrate less disruptive behavior and irritable mood
simply because improved cognition has led to better social
integration and reduced environmental stress.
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in Mood Disorders and Schizophrenia
In both mood disorders and schizophrenia cognitive defi-
cits are common as well as are behavioral and mood
disturbances [33]. Whereas in mood disorders the primary
focus was on the ability of cholinergic systems to normal-
ize depression or mania, in schizophrenia the main focus
was on the association of cognitive and functional deficits.
Burt et al. [34•] reported a case series of 11 patients with
treatment-resistant bipolar disorder who received donepezil
for a period of 6 weeks or more. Six patients had an
improvement of two points or more on the Clinical Global
Impression-Severity of Illness (CGI-S) [35], a seven-point
scale. Five of the patients that improved demonstrated
improvement within the first 2 weeks. Of note, one of the
patients suffered from bipolar depression and demonstrated
a three-point improvement on the CGI-S. Improvement of
depression with ChEIs can be explained by the agonistic
effect on nicotinic receptors. Nicotine may posses anti-
depressant effects as is suggested by the comorbidity of
depression and nicotine dependence, as well as by the
demonstrated efficacy of antidepressants in the treatment of
nicotine dependence (eg, bupropion). If, in addition, ChEIs
exert antimanic effects as well, through agonist activity on
muscarinic receptors, ChEIs may be considered true
bimodal mood-stabilizing agents.
In schizophrenia, Risch et al. [36] reported improve-
ments in verbal fluency and attention in six patients on
donepezil. Concurrent activation of the right dorsolateral
prefrontal cortex and anterior cingulated on functional
magnetic vesonance imaging was also observed. Bergman et
al. [37] reported a case study of a patient with schizophrenia,
resistant to clozapine, haloperidol, and fluphenazine, and
partially responding to risperidone, that experienced
improvement in psychotic symptoms and cognitive
function within 4 weeks of starting donepezil. The patient
maintained these improvements at a 6-month follow-up.
Donepezil treatment was also associated with improved
behavioral functioning and performance in neurocognitive
test batteries in two treatment refractory patients with schizo-
phrenia, in an open-label treatment [38]. Burke et al. [39]
reported the resolut ion of  postoperat ive  v isual
hallucinations in a 74-year-old man after starting donepezil.
Cholinesterase Inhibitors in Tourette's 
Disorder and Attention Deficit 
Hyperactivity Disorder
Recent literature on tic disorders has focused on serotonin
and dopamine, although reports of improvement in tics
with nicotine treatment suggest a role for acetylcholine as
well. Tacrine was associated with a significant decline in
self-rated attentional deficits, a significant improvement
in objective measures of sustained attention, and a near-
significant decrease in examiner-rated tics in an open-label
study involving six patients with Tourette’s disorder [40].
Hoopes et al. [41] reported on two patients, 11 and 13 years
old, both with Tourette's disorder and attention deficit
hyperactivity disorder (ADHD), resistant to standard
therapy who experienced a decrease in frequency and
intensity of tics within days of starting donepezil, and
maintained improvement in both tics and attention-related
symptoms for 8 months. Because dopamine is known to
inhibit acetylcholine interneurons in the striatum, a
relationship evident in extrapyramidal syndrome as a result
of dopamine blockade by neuroleptics, these reports
suggest that acetylcholine may reciprocally decrease
dopamine tone and thus improve some tics [41].
Cholinesterase Inhibitors in Other Disorders
Lanctot et al. [42] reported on a case series of seven
patients with dementia with Lewy bodies. These often
neuroleptic-resistant patients with significant behavioral
disturbances were treated with donepezil in an open label
basis. Three patients demonstrated marked improvement
as measured by the NPI and two more had improved
minimally. Four patients did not complete the intended
8-week treatment period due to side effects or lack
of response.
Wengel et al. [43] reported on a case of delirium
complicating a preexisting dementia that resolved rapidly
following initiation of donepezil. Because cholinergic
dysfunction may play a role in the etiology of delirium
a trial of donepezil may be appropriate in cases of
unknown etiology.
In another anecdotal report, Kishnani et al. [44]
described four patients with Down's syndrome treated for
an average duration of therapy with donepezil of about 9
months. The following were observed: improvements in
communication, expressive language, attention, mood
stability, socialization, and adaptive behavior.
Green et al. [45] conducted a 12-week, open-pilot study
in 17 patients with multiple sclerosis and cognitive impair-
ment to assess the efficacy and tolerability of donepezil,
and reported significant improvement in behavior,
attention, memory, and executive functioning.
Cholinesterase Inhibitors as Diagnostic Tools
Abnormalities of CNS cholinergic tone have been found in
a variety of psychiatric disorders [46]. The possibility that
such abnormalities may constitute a biological marker and
lend themselves to a quick, noninvasive, and inexpensive
test such as the administration of a ChEI, led to a variety of
studies in this area.
Major depression is reliably associated with REM sleep
abnormalities, suggesting increased cholinergic activation,
enhanced cholinergic sensitivity or imbalance in cholinergic
and monoaminergic tone. Giles et al. [47•] reported that
cholinergic challenge using donepezil distinguished between
eight depressed patients and eight controls by significantly
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controls. These results suggest that donepezil can provide a
pharmacologic probe of cholinergic tone.
Cooney et al. [48,49] examined the specificity of the
growth hormone release in response to challenge with the
ChEI pyridostigmine in a variety of psychiatric disorders
and in healthy controls. Growth hormone response to the
challenge was significantly greater in patients with major
depression and panic disorder when compared with
healthy controls. Responses in patients with schizophrenia
and alcohol dependence did not differ from the control
group. The test demonstrated a sensitivity of 63% for
major depression.
Rubin et al. [50] used physostigmine challenge and
measures of subsequent changes in plasma arginine
vasopressin (AVP), ACTH, and cortisol to differentiate
between groups of patients with major depression. Their
results were consistent with a heightened cholinergic sensi-
tivity in premenopausal women, but not in men with
major depression.
Steinberg et al. [51] found a significant increase in
depressive symptoms following physostigmine infusion
when compared to placebo in patients with borderline
personality disorder (BPD) but not other personality
disorders, when compared with normal controls. The
study was conducted in 34 patients with personality
disorder (10 with BPD) and 11 normal controls [51].
Conclusions
Donepezil as well as other acetylcholinesterase inhibitors
appear to have effects on human mood and behavior.
Recent years have witnessed a growing number of prelimi-
nary observations with the newly introduced orally admin-
istered forms of cholinesterase inhibitors. Applications for
cholinesterase inhibitors included both diagnostic and
therapeutic interventions. Specifically, studies suggest that
cholinesterase inhibitors may be useful in the diagnosis of
depression and personality disorders, and that they
may have mood and behavioral normalizing effects on
symptoms such as depression, mania, apathy, delusions,
hallucinations, and delirium, in conditions such as bipolar
disorder, schizophrenia, Tourette's disorder, and delirium.
Donepezil was involved in the largest number of studies
and was associated with the largest number of positive
results. In view of the established beneficial effect of ChEIs
on cognition, and considering the close relationship
between systems that regulate cognition, mood, and
behavior in the CNS, further controlled studies are needed
to establish a primary effect of ChEIs on mood and
behavior and to clarify the diagnostic and therapeutic
value of ChEIs as pharmacologic modulators of human
mood and behavior.
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